CA
NZ
UK
AU
IND
US
…
Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Acrux Limited is an Australian specialty pharmaceutical company developing and commercializing topical and transdermal drug-delivery and consumer health products using proprietary technologies. Long-term growth may be driven by regulatory approvals, licensing or partnership deals and sales or royalties from commercialized products, making the technology platform and recurring income potential of interest to investors.
Principal risks include regulatory and clinical setbacks, reliance on licensing partners, limited scale and liquidity, and execution or financing constraints.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -0.21M | -9.58M | -12.43M | -9.38M | -8.34M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -0.76M | -9.83M | -12.63M | -9.47M | -8.32M |
| Selling general administrative | 5.77M | 6.08M | 6.36M | 5.94M | 6.21M |
| Gross profit | 7.87M | 1.72M | 1.34M | 1.25M | 0.63M |
| Reconciled depreciation | 0.59M | 0.66M | 0.67M | 0.71M | 0.43M |
| Ebit | -3.07M | -12.97M | -16.25M | -12.08M | -12.99M |
| Ebitda | -2.47M | -12.31M | -15.59M | -11.37M | -12.56M |
| Depreciation and amortization | 0.59M | 0.66M | 0.67M | 0.71M | 0.43M |
| Non operating income net other | - | - | - | - | 0.00M |
| Operating income | -3.07M | -12.97M | -16.25M | -12.08M | -12.99M |
| Other operating expenses | 11.82M | 14.69M | 17.59M | 13.33M | 13.62M |
| Interest expense | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.55M | 0.25M | 0.20M | 0.09M | -0.01M |
| Interest income | 0.12M | 0.02M | 0.03M | 0.22M | 0.58M |
| Net interest income | 0.12M | 0.02M | 0.03M | 0.22M | 0.58M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | 0.55M | 0.25M | 0.20M | 0.09M | -0.01M |
| Total revenue | 8.43M | 1.72M | 1.34M | 1.25M | 0.63M |
| Total operating expenses | 11.26M | 14.69M | 17.59M | 13.33M | 13.62M |
| Cost of revenue | 0.56M | - | - | - | 5.12M |
| Total other income expense net | 3.06M | 3.37M | 3.79M | 2.48M | 4.08M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -0.76M | -9.83M | -12.63M | -9.47M | -8.32M |
| Net income applicable to common shares | -0.76M | -9.83M | -12.63M | -9.47M | -8.32M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 8.96M | 13.29M | 14.30M | 23.33M | 17.84M |
| Intangible assets | - | - | 0.38M | 0.48M | 0.59M |
| Other current assets | 0.15M | 0.04M | - | 0.17M | - |
| Total liab | 5.69M | 4.59M | 5.21M | 4.86M | 4.99M |
| Total stockholder equity | 3.28M | 8.70M | 9.09M | 18.47M | 12.85M |
| Deferred long term liab | - | - | 0.38M | 0.48M | 0.59M |
| Other current liab | 1.51M | 1.71M | 2.31M | 2.27M | 1.47M |
| Common stock | 115.01M | 114.88M | 114.56M | 114.21M | 96.14M |
| Capital stock | 115.01M | 114.88M | 114.56M | 114.21M | 96.14M |
| Retained earnings | -120.29M | -114.49M | -113.72M | -103.89M | -83.87M |
| Other liab | - | 0.04M | 0.04M | 0.04M | 0.09M |
| Other assets | - | 0.80M | 1.73M | 2.09M | 2.39M |
| Cash | 2.94M | 6.23M | 5.83M | 15.27M | 9.21M |
| Total current liabilities | 3.72M | 2.39M | 3.32M | 2.77M | 2.67M |
| Current deferred revenue | 0.94M | - | - | - | - |
| Net debt | 0.76M | -3.88M | -3.75M | -13.04M | -6.80M |
| Short term debt | 1.78M | 0.19M | 0.22M | 0.18M | 0.17M |
| Short long term debt | 1.49M | - | - | - | - |
| Short long term debt total | 3.70M | 2.35M | 2.08M | 2.23M | 2.40M |
| Other stockholder equity | - | 0.91M | 0.86M | 0.76M | 0.58M |
| Property plant equipment | - | 2.59M | 2.56M | 2.64M | 3.10M |
| Total current assets | 5.98M | 9.89M | 10.02M | 18.59M | 12.34M |
| Net tangible assets | - | 8.70M | 9.09M | 18.47M | 12.85M |
| Net receivables | 2.89M | 3.31M | 3.77M | 3.16M | 2.56M |
| Inventory | - | 0.32M | - | - | - |
| Accounts payable | 0.43M | 0.49M | 0.79M | 0.31M | 1.02M |
| Accumulated other comprehensive income | 8.55M | 8.30M | 8.25M | 8.15M | 0.58M |
| Non current assets total | 2.98M | 3.39M | 4.29M | 4.73M | 5.49M |
| Capital lease obligations | 2.22M | 2.35M | 2.08M | 2.23M | 2.40M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.12M | -0.47M | -0.10M | -0.25M | -0.38M |
| Change to liabilities | -0.29M | 0.69M | 0.09M | 0.09M | -0.10M |
| Total cashflows from investing activities | -0.12M | -0.47M | -0.10M | -0.25M | -0.38M |
| Net borrowings | -0.18M | -0.15M | -0.17M | -0.16M | -0.16M |
| Total cash from financing activities | -0.18M | -0.15M | 17.58M | -0.16M | -0.16M |
| Change to operating activities | 0.02M | -0.18M | 0.55M | -0.00M | -0.24M |
| Net income | -0.76M | -9.83M | -12.63M | -9.47M | -8.32M |
| Change in cash | 0.40M | -9.44M | 6.06M | -8.95M | -10.32M |
| Begin period cash flow | 5.83M | 15.27M | 9.21M | 18.15M | 28.47M |
| End period cash flow | 6.23M | 5.83M | 15.27M | 9.21M | 18.15M |
| Total cash from operating activities | 0.70M | -8.82M | -11.41M | -8.53M | -9.94M |
| Issuance of capital stock | - | - | 17.75M | - | - |
| Depreciation | 0.86M | 0.55M | 0.56M | 0.60M | 0.32M |
| Other cashflows from investing activities | - | - | - | - | 0.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | 0.46M | -0.61M | -0.60M | -0.25M | -2.04M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -0.18M | -0.15M | -0.17M | -0.16M | -0.38M |
| Change to netincome | 0.37M | 0.45M | 0.51M | 0.39M | 0.28M |
| Capital expenditures | 0.12M | 0.47M | 0.10M | 0.26M | 0.38M |
| Change receivables | - | - | - | - | 0.00M |
| Cash flows other operating | - | - | - | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | - | - | - | - | 0.00M |
| Free cash flow | -0.12M | -0.47M | -0.10M | -0.26M | -0.38M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARUXF Acrux Limited |
- -% |
0.00 | - | - | 1.71 | 4.17 | 2.49 | -0.87 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
103-113, Stanley Street, West Melbourne, VIC, Australia, 3003
61 3 8379 0100
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | CEO, MD & Exec. Director | 1966 |
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Sec. | NA |
| Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA | Product Devel. & Technical Affairs Director | NA |
| Mr. Charles O'Sullivan B. Pharm | Portfolio Director | NA |
| Mr. Mark Hyman | Project & Technical Devel. Director | NA |
| Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | CEO, MD & Executive Director | 1966 |
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...